Coste-efectividad de una estrategia de cribado del virus de la hepatitis B para prevenir la reactivación en pacientes con neoplasia hematológica

Crespo, Javier; Esteban, Rafael; Torres, Covadonga; Oyagüez, Itziar; Casado, Miguel Ángel; Buti, María.
Rev. esp. enferm. dig ; 109(9): 619-626, sept. 2017. tab, ilus
Artigo em Espanhol | IBECS (Espanha) | ID: ibc-165847

Documentos relacionados

  1. Cost-effectiveness of a hepatitis B virus screening strategy to prevent reactivation in patients with hematologic neoplasms.
  2. Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy.
  3. The Ambulatory Medical Assistance (AMA) programme during active-phase treatment in patients with haematological malignancies: A cost-effectiveness analysis.
  4. Developing a classification of hematologic neoplasms in the era of precision medicine.
  5. [Efficacy and safety analysis of umbilical cord blood combined with haploid hematopoietic stem cell transplantation in the treatment of malignant hematological malignancies].
  6. Comprehensive review of post-organ transplant hematologic cancers.
  7. Screening for multidrug-resistant organisms in high-risk hospitalized patients with hematologic diseases.
  8. EQ-5D-Derived Health State Utility Values in Hematologic Malignancies: A Catalog of 796 Utilities Based on a Systematic Review.
  9. Antithrombotic secondary prophylaxis with low dose of apixaban or rivaroxaban in the onco-hematologic patients: comparison with non-neoplastic patients.
  10. A framework for the clinical implementation of optical genome mapping in hematologic malignancies.